Saint Francis Hospital and Medical Center
The Mandell MS Center


Host to the Multiple Sclerosis Brain Symposium 2016 | About Joyce and Andy Mandell


Responsiveness to Dalfampridine Treatment Among Multiple Sclerosis Patients Followed at the Mandell Multiple Sclerosis Center Identifier: NCT01399957 

Mount Sinai Hospital
490 Blue Hills Ave
Hartford, CT 06112

Short Description
Ampyra (dalfampridine) has been approved by the FDA for improving walking speed in persons with multiple sclerosis (MS). This observational study was designed to capture information on additional possible benefits person’s taking Ampyra may or may not experience. This project seeks to determine factors that will predict a response (an increase in walking speed) to dalfampridine. A second goal is to identify possible additional benefits to taking Dalfampridine.

Status Active, but not recruiting

Principal Investigator Albert Lo, MD, PhD, Elizabeth Triche, PhD

Contact Kayla Olson, Research Associate

Phone (860) 714-2149


The Mandell MS Center
490 Blue Hills Avenue
Hartford, CT 06112